Navigation Links
Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
Date:7/11/2013

LANDOVER, Md., July 11, 2013 /PRNewswire-USNewswire/ -- The Epilepsy Foundation, a national organization dedicated to serving all people with seizures, today launched the Epilepsy Innovation Seal of Excellence (SEAL), an award that recognizes groundbreaking and innovative product development programs deemed by the Foundation as deserving of significant and urgent support.  The launch of the SEAL is part of the Foundation's strategic mandate to recognize critical advancements in the field of epilepsy.  The SEAL is designed to facilitate access to funding and resources that will carry the recipient's work through proof of concept (PoC) and beyond, which typically costs from $1 million to $5 million dollars. 

(Logo: http://photos.prnewswire.com/prnh/20130612/DC30930LOGO)

The award is given after intense scrutiny by the Scientific and Business Advisory Boards of the Epilepsy Foundation's Epilepsy Therapy Project (ETP) Initiative.  ETP is focused on identifying and accelerating the most innovative epilepsy products in development.  The SEAL includes a prize of $25,000 and the privilege of using the Foundation's Epilepsy Innovation Seal of Excellence in advancing their efforts (http://www.epilepsy.com/etp/seal_of_excellence).

The Epilepsy Foundation is honored to announce the recipients of the first two SEAL awards:

  • AurimMed Pharma of Park City, Utah is advancing an exciting anti-seizure drug AMP-X-0079 that has already demonstrated promising early-stage data in the National Institute of Neurological Disorders and Stroke (NINDS) Anticonvulsant Screening Program.  The company is currently seeking $1.9 million to prepare AMP-X-0079 for an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration, taking this program into human clinical studies.  (www.aurimmed.com)
  • The second SEAL recipient is Hovding of Malmo, Sweden for their revolutionary airbag helmet. The product was originally designed to protect cyclists, but also has the potential to offer significant safety features for people with epilepsy.  The goal for Hovding is to obtain $4 million to adapt the bicycle device for falls during seizures and to make the airbag reusable. (www.Hovding.com)

"When it comes to money spent on research and innovation, the epilepsy community is tremendously underserved -- especially in comparison to medical conditions of similar or smaller prevalence," said Roger J. Porter, MD, Chief Scientific Officer of the Epilepsy Foundation. "With this SEAL, we have recognized innovative projects in urgent need of funding and resources."

The Epilepsy Innovation Seal of Excellence will be awarded biannually by the Epilepsy Foundation. Companies, investigators and researchers engaged in product development are encouraged to share research and product development programs of high merit and proof of concept with the Foundation (http://my.epilepsy.com/etp/seal_of_excellence/about). 

"The Epilepsy Innovation Seal of Excellence represents our commitment to advancing important new products for the betterment of persons with epilepsy worldwide," said Philip M. Gattone, President and CEO of the Epilepsy Foundation.  "Our first prize winners were selected for their potential to improve the quality of life for people with epilepsy in a timeframe that matters. I hope support from the Epilepsy Foundation helps mobilize funding from other investors, government agencies and industry participants to make these important innovations real options for people with epilepsy. "

"The Epilepsy Therapy Project's mandate is to accelerate pioneering epilepsy research, especially with near-term potential, and we recognize the need to assist in finding resources for critical but expensive innovations," said Warren Lammert, Chairman of the Board of the Epilepsy Foundation.  "The Epilepsy Innovation Seal of Excellence is an expression of our commitment to build the Epilepsy Foundation as a leader in driving new therapies and other innovations." 

About Epilepsy
When a person has two or more unprovoked seizures, they have epilepsy, which affects nearly three million people in the United States and 65 million people worldwide.  This year, another 200,000 people in our country will be diagnosed with epilepsy.  Despite all available treatments, four out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control.

About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with affiliated organizations throughout the United States, has led the fight against seizures since 1968.  The Foundation's goals are to ensure that people with seizures are able to participate in all life experiences; and to prevent, control and cure epilepsy through services, education, advocacy and research, so not another moment is lost to seizures.

To learn more about epilepsy, visit www.epilepsy.com.  'Like' the Epilepsy Foundation on Facebook at www.facebook.com/epilepsyfoundationofamerica and follow us on Twitter at www.twitter.com/epilepsyfdn


'/>"/>
SOURCE Epilepsy Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
2. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
3. Elsevier Launches New Open Access Journal - Epilepsy & Behavior Case Reports
4. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
5. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
6. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
7. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
10. NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder
11. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):